Literature DB >> 28606272

[Progression of the pathogenesis of thyroid associated ophthalmopathy].

L Wang1, J M Ma.   

Abstract

Thyroid associated ophthalmopathy (TAO) is a common complication of Graves' disease (GD). The clinical manifestations are mainly swelling and retracted eyelid, protopsis and limited eye movements, and optic neuropathy can be seen in severe cases. The mechanism of TAO is not yet clear. A large number of studies have found that the disorders of autoimmunity play an important role in TAO, while genetic factors, oxidative stress, and environmental factors such as smoking participate in it. Therefore, we consult a large number of studies and expound the pathogenesis from the aspects of genetic susceptibility, immune mechanism, oxidative stress, and the effects of smoking to provide referrences for clinical associated studies. (Chin J Ophthalmol, 2017, 53: 474-480).

Entities:  

Keywords:  Autoimmunity; Genetic predisposition to disease; Graves ophthalmopathy; Oxidative stress; Smoking

Mesh:

Year:  2017        PMID: 28606272     DOI: 10.3760/cma.j.issn.0412-4081.2017.06.018

Source DB:  PubMed          Journal:  Zhonghua Yan Ke Za Zhi        ISSN: 0412-4081


  3 in total

1.  Preliminary study of abnormalities in saccade dynamics in patients with hyperthyroidism with no pre-existing eye damage.

Authors:  Yan Sun; Xinhui Xie; Yongxia Xu; Chen Wang; Xiaoming Kong
Journal:  Exp Ther Med       Date:  2020-01-17       Impact factor: 2.447

2.  Altered peripapillary vessel density and nerve fiber layer thickness in thyroid-associated ophthalmopathy using optical coherence tomography angiography.

Authors:  Huan Jian; Yujiao Wang; Luyu Ou; Weimin He
Journal:  Int Ophthalmol       Date:  2021-10-12       Impact factor: 2.031

3.  MicroRNA-146a downregulates the production of hyaluronic acid and collagen I in Graves' ophthalmopathy orbital fibroblasts.

Authors:  Wei Liu; Chao Ma; Hao-Yu Li; Lan Chen; Shan-Si Yuan; Kai-Jun Li
Journal:  Exp Ther Med       Date:  2020-09-01       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.